We just finished reading a terrific academic piece by Jack Scannell and colleagues at the University of Oxford. Entitled Financial Returns on R&D: Looking Back at History, Looking Forward…
Earlier this month, our friends at Biotech and Money published a transcript from a panel discussion at their London 2015 congress. The discussion was quite interesting, and we encourage…
We've started preparing for the BIO convention in Philadelphia in June. Preparing? Already? Yes. Why start now? We'll give you three reasons: New Partnering Interface - BIO has unveiled a…
From a consulting perspective, here is how we view business development, using the acronym LUNCH: Learn what the client wants: What is the objective? Is it cash now in the…
Earlier this week, BIO released what we think is a valuable and important report. Entitled Venture Funding of Therapeutic Innovation, the report analyzes data on venture funding in R&D by…
Lisa Jarvis has prepared a handy overview of the new drug approvals in 2014: For the pharmaceutical industry, 2014 was one for the record books: sky-high merger and acquisition activity, unprecedented…
Today, Bruce Booth published yet another terrific post, where he discusses the current biotech investment bubble from the private world of venture backed biotechs (and, he puts many mainstream journalists…
A few weeks ago, BIO conducted an interesting panel discussion as part of their run up to the BIO Latin America Conference taking place the week in Brazil. The…
This morning we learned that Sanofi is the winner in the "Where on Earth is the Partner for Afrezza?" sweepstakes. We'll defer to the many news outlets for…
Yes, and it might be worth it. Yesterday, Daiichi Sankyo announced an incredible $650 million deal with Florida-based Charleston Laboratories for the development and commercialization of a family of fixed…